Monitor for any prospectus supplement indicating the timing and method of BMS's resale. The overhang is modest at 3.7% of shares outstanding, but BMS has no standstill restrictions and may sell at any time. The elimination of milestone/royalty obligations removes a future cash outflow, which is a positive structural change.
Drugs in focus
IMNM drug pipeline →varegacestat
▲ Bullish Named in this S-3ASR- Impact
- Phase
- Filed/PDUFA
- Time to market
- FDA PDUFA target action date is April 28, 2027. EMA review is also underway following MAA validation in October 2026. If approved, varegacestat could launch in the US in the second half of 2027.
- Next catalyst
- PDUFA date · Apr 28, 2027 162d
What to watchThe single most important catalyst is the FDA PDUFA decision on April 28, 2027. Approval would make varegacestat the second FDA-approved therapy for desmoid tumors and unlock a meaningful commercial opportunity, while a Complete Response Letter would severely pressure the stock given the company's pre-revenue status and reliance on this asset. Watch for EMA review progress and Q3 earnings on November 16 for pipeline updates and cash runway details.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $18.65entry
- T+1 · 6d ago +2.25%α +0.93% · $19.07
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immunome filed an automatic shelf registration statement (S-3ASR) to register 4,425,487 shares of common stock for resale by Bristol-Myers Squibb Company (BMS). These shares were issued to BMS on October 2, 2026, as part of the consideration to terminate all milestone and royalty obligations under the varegacestat license agreement. Immunome will not receive any proceeds from the resale. The filing is a routine registration obligation, not a new capital raise.
Key Facts
- Registration covers 4,425,487 shares of common stock for resale by BMS.
- Shares were issued to BMS on October 2, 2026, as consideration for Amendment No. 4 to the License Agreement.
- Immunome paid BMS $20.0 million in cash and issued the shares to eliminate all future milestone and royalty obligations under the varegacestat license.
- Immunome will not receive any proceeds from the resale of these shares.
- BMS held 3.7% of outstanding shares prior to the offering, based on 118,072,943 shares outstanding as of November 4, 2026.
- The maximum aggregate offering price is approximately $81.2 million, based on the average of high and low prices on November 5, 2026.
- The filing is a registration obligation under the Stock Issuance Agreement, not a new primary offering.
Financial Impact
No new capital raised. Potential overhang from BMS resale of up to 4.4M shares (3.7% of shares outstanding), valued at approximately $81.2M at the reference price.
Risk Factors
- Potential overhang from BMS resale of 4.4M shares, though the amount is modest relative to market cap.
- BMS is not subject to any standstill restrictions and may sell shares at any time.
- The company has a history of frequent equity offerings (6 offering/registration filings in the last 24 months), which may signal ongoing capital needs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3ASR Filing (Primary) | 0001193125-26-453780 |
| Document: d190058dexfilingfees.htm | 0001193125-26-453780 |
| Document: d190058dex51.htm | 0001193125-26-453780 |
| Document: d190058dex231.htm | 0001193125-26-453780 |
| Document: 0001193125-26-453780-index-headers.html | 0001193125-26-453780 |
| Document: 0001193125-26-453780-index.html | 0001193125-26-453780 |
| Document: 0001193125-26-453780.txt | 0001193125-26-453780 |
Track record
20 reports on IMNM
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.53% at T+60 after the May 28, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Viewing Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $18.65 Now $17.61 +5.58% settles Feb 8
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
- Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
- Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Entry $20.89 Now $17.61 +15.70% settles Dec 28
- Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Entry $25.07 Now $17.61 −29.76% settles Dec 15
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers